tarhan, tuba medipol üniversitesi - tıp fakültesi, sefaköy hastanesi, kadın hastalıkları ve doğum kliniği, Turkey , eken, meryem kürek adnan menderes üniversitesi - tıp fakültesi - kadın hastalıkları ve doğum ana bilim dalı, Turkey , ilhan, gülşah süleymaniye kadın doğum ve çocuk hastalıkları eğitim ve araştırma hastanesi, turkey , karateke, ateş zeynep kamil kadın ve çocuk hastalıkları eğitim ve araştırma hastanesi - kadın hastalıkları ve doğum kliniği, Turkey

EVALUATION OF PERINATAL OUTCOMES OF PREGNANCIES HAVING INCREASED NUCHAL TRANSLUCENCY IN FIRST TRIMESTER SCREENING TEST AND NORMAL KARYOTYPE

26014

Objective: To assess the perinatal outcomes of fetuses having nuchal translucency (NT) greater than 2.5 mm and with normal karyotype. Materials and Methods: Results of pregnancies with an increased nuchal translucency (95. percentile and above) in the first trimester screening test and those with karyotyping were examined retrospectively. Cases without chromosomal abnormalities were evaluated for the maternal age, obstetric and family history. Information about the outcomes of pregnancies and any abnormalities detected during pregnancy/ neonatal /infancy / childhood follow- ups were obtained by telephone interviews. Results: A case that had 7.2 mm NT had been terminated due to major cardiovascular abnormalities. One fetus in twin pregnancy that had 2.8 mm NT resulted in missed abortion in 13 weeks of gestation and intrauterine growth restriction developed in the other euploid fetus and resulted in utero exitus at 23 weeks of gestation. Other two cases having 2.8 mm NT resulted in utero fetal demise at 16 weeks and 30 weeks. Another case having 3.9 mm NT who had mild pyelectasis had normal renal pelvic diameter in the neonatal period. Hypospadias was diagnosed postpartum in another fetus with 2.9 mm NT. Conclusion: Even among fetuses with normal karyotype, NT 95th percentiles may present an increased risk for in utero fetal death, major structural abnormalities, genetic syndromes and neurological developmental problems. Families should be informed about it and follow-up processes should be continued throughout the newborn, infancy and childhood period.

117

Second trimester screening test , karyotype , nuchal translucency.

Journal Of Istanbul Faculty Of Medicine

122